Abstract
Medical progress has placed cytomegalovirus (CMV) as one of the most important viral pathogens for which treatment is limited and a vaccine is not yet available. The limited treatment options for CMV triggered efforts to discover new antivirals. Drug screening raised hope but also uncertainties as to whether drug repurposing may be a practical approach for infectious diseases in general and CMV in particular. I summarize here several of such agents as well as an approach to advance repurposing for CMV therapy.
Original language | English (US) |
---|---|
Pages (from-to) | 103-109 |
Number of pages | 7 |
Journal | Future Virology |
Volume | 12 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2017 |
Keywords
- artemisinins
- congenital infection
- cytomegalovirus
- drug development
- emetine
- immunosuppressive agents
- repurposing
- transplantation
ASJC Scopus subject areas
- Virology